Differences in Initial Benign Prostatic Hyperplasia Management Between Primary Care Physicians and Urologists

Journal of Urology

Volumn 182, Issue 5, 2009, Pages 2410-2414

  Hollingsworth, John M ^a   Hollenbeck, Brent K ^a,b   Daignault, Stephanie ^c   Kim, Simon P ^a   Wei, John T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Michigan Surgical Collaborative for Outcomes Research and Evaluation   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

epidemiology; medical; physician's practice patterns; prostatic hyperplasia; specialties; statistics and numerical data

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HEALTH CARE ORGANIZATION; HUMAN; INTRAVENOUS UROGRAPHY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL CARE; MEDICAL SPECIALIST; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; URINALYSIS; URODYNAMICS; UROLOGY; COMPARATIVE STUDY; MIDDLE AGED; PRIMARY HEALTH CARE;

ADULT; AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; UROLOGY;

EID: 70350462182     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.07.029     Document Type: Article

References (20)

1. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 335 (1996) 533
2. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 (1998) 557
3. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
4. Wei J.T., Calhoun E., and Jacobsen S.J. Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol 173 (2005) 1256
5. Fendrick A.M., Hirth R.A., and Chernew M.E. Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease. Am J Gastroenterol 91 (1996) 1544
6. Greenfield S., Nelson E.C., Zubkoff M., et al. Variations in resource utilization among medical specialties and systems of care. Results from the medical outcomes study. JAMA 267 (1992) 1624
7. Markson L.E., Cosler L.E., and Turner B.J. Implications of generalists' slow adoption of zidovudine in clinical practice. Arch Intern Med 154 (1994) 1497
8. Ayanian J.Z., Hauptman P.J., Guadagnoli E., et al. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 331 (1994) 1136
9. Jollis J.G., DeLong E.R., Peterson E.D., et al. Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med 335 (1996) 1880
10. Fenter T.C., Naslund M.J., Shah M.B., et al. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care 12 (2006) S90
11. Red Book 1995: Drug Topics (1995), Medical Economics Co, Montvale, New Jersey
12. Hosmer D.W., and Lemeshow S. Applied Logistic Regression (2000), John Wiley & Sons, Inc, New York
13. Klabunde C.N., Potosky A.L., Legler J.M., et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 53 (2000) 1258
14. Panageas K.S., Schrag D., Riedel E., et al. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med 139 (2003) 658
15. White H. A teteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 48 (1980) 817
16. Stukel T.A., Fisher E.S., Wennberg D.E., et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 297 (2007) 278
17. Roehrborn C.G., McConnell J.D., Barry M.J., et al. Guideline on the Management of Benign Prostatic Hyperplasia (BPH) (2003), American Urological Association, Baltimore, Maryland
18. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 283 (2000) 1967
19. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group: Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42 (2003) 239
20. NCS Pearson. 2003 Michigan Consumer Assessment of Health Plans Survey. www.michigan.gov/documents/Medicaid2003survey_95643_7.pdf Accessed December 24, 2007